Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)

Trial Profile

Phase IIIb Study Minimizing Adverse Haemmhorragic Events by TRansradial Access Site and Systemic Implementation of angioX (MATRIX)

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2018

At a glance

  • Drugs Bivalirudin (Primary) ; Abciximab; Eptifibatide; Heparin; Tirofiban
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms MATRIX; MATRIX-Access
  • Most Recent Events

    • 25 Aug 2018 Final 1-year results published in The Lancet.
    • 11 May 2017 Results assessing the risk of AKI associated with Radial Access or Femoral Access in patients from AKI-MATRIX Substudy (n=8210), published in the Journal of the American College of Cardiology
    • 01 Sep 2015 Results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top